Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.57 |
| ▸ | SIK1 | P57059 | 6/20 | 0.47 |
| ▸ | SIK2 | Q9H0K1 | 6/20 | 0.47 |
| ▸ | SIK3 | Q9Y2K2 | 6/20 | 0.47 |
| ▸ | CSF1R | P07333 | 3/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19902565 | 0.93 | USP30 (0.47) | USP30SIK1SIK2SIK3CSF1R | |
| SCHEMBL19902619 | 0.91 | SIK1 (0.47) | USP30SIK1SIK2SIK3CSF1R | |
| SCHEMBL17452889 | 0.90 | USP30 (0.53) | USP30SIK1SIK2SIK3CSF1R | |
| SCHEMBL19902560 | 0.89 | USP30 (0.44) | USP30SIK1SIK2SIK3CSF1R | |
| SCHEMBL19902563 | 0.89 | USP30 (0.45) | USP30SIK1SIK2SIK3CSF1R | |
| SCHEMBL19902584 | 0.89 | USP30 (0.45) | USP30SIK1SIK2SIK3CSF1R | |
| SCHEMBL19902588 | 0.88 | CSF1R (0.45) | USP30SIK1SIK2SIK3CSF1R | |
| SCHEMBL19902394 | 0.86 | SIK1 (0.42) | USP30SIK1SIK2SIK3CSF1R | |
| SCHEMBL19902368 | 0.86 | ROCK1 (0.49) | USP30CSF1RROCK1KITROCK2 | |
| SCHEMBL19902610 | 0.85 | CSF1R (0.55) | SIK1SIK2SIK3CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | USP30 3527/4885SIK1 1531/4885SIK2 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.